Previous 10 | Next 10 |
The FDA grants Fast Track designation to Immutep's (IMMP) lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, for the treatment of 1st line recurrent or metastatic head and neck squamous cell carcinoma ((HNSCC)).Fast Tr...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immutep (NASDAQ: IMMP ) stock is soaring higher in Thursday’s pre-market after the biotech said it received a patent from European regulators for one of its antibodies used as a combination therapy. IMMP stock ...
Fast Track designation opens the potential for expedited development and review with the US FDA Fast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase II TACTI-002 trial (Keynote-798) in head and neck squamous cell carcinoma (HNS...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to buckle down in preparation for another day of trading as pre-market movers see gains and losses. While the end of the week is quickly approaching, investors can’t relax just yet. Source: Shutt...
Immutep (IMMP) announces the grant of patent number EP3317301 entitled "Combination therapies comprising antibody molecules to LAG-3" by the European Patent Office.The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is...
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announ...
Hot Penny Stocks to Watch If Biotech is Your Focus Investors continue looking for the best penny stocks to buy. With the way the stock market has been lately, that’s easier said than done. But the potential that these cheap shares bring is unlike anything else out there. ...
Gainers: [[TLS]] +21.3%. [[IMMP]] +13.1%. [[PRTK]] +6.5%. [[WIMI]] +3.8%. [[YY]] +3.4%.Losers: [[CRMD]] -8.9%. [[SYBX]] -5.3%. [[PRQR]] -4.7%. [[CD]] -4.6%. [[OLK]] -3.9%. For further details see: TLS, IMMP, CRMD and SYBX among after-hours movers
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immutep Limited (NASDAQ: IMMP ) stock is soaring higher on Thursday despite a lack of recent news coming from the company. Source: CI Photos / Shutterstock.com Even so, that isn’t stopping the heavy tra...
Gainers: ProQR Therapeutics (PRQR) +47%.Cellect Biotechnology (APOP) +47%.Houston Wire & Cable (HWCC) +38%.GameStop (GME) +29%.Koss (KOSS) +28%.Cinedigm (CIDM) +28%.F-star Therapeutics (FSTX) +26%.FreightCar America (RAIL) +24%.Polar Power (POLA) +20%.Immutep (IMMP) +20%.Losers:...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...